In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens | Zendy

Gerald A. Denys | Zendy; P. Grover | Zendy; P O’Hanley | Zendy; Jackson T. Stephens | Zendy

Open Access

In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens

Author(s) -

Gerald A. Denys,

P. Grover,

P O’Hanley,

Jackson T. Stephens

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq429

Subject(s) - enterococcus faecalis , microbiology and biotechnology , antimicrobial , pseudomonas aeruginosa , staphylococcus aureus , enterococcus , streptococcus pyogenes , myeloperoxidase , streptococcus agalactiae , gram positive bacteria , antibiotics , enterobacteriaceae , antibiotic resistance , biology , streptococcus , escherichia coli , bacteria , immunology , biochemistry , inflammation , gene , genetics

E-101 Solution (E-101) is a novel myeloperoxidase-mediated antimicrobial. It is composed of porcine myeloperoxidase (pMPO), glucose oxidase, glucose as the substrate and specific amino acids in an aqueous vehicle. E-101 is being developed for topical application directly into surgical wounds to prevent surgical site infections (SSIs). The in vitro activity of E-101 was investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research